Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
for Renal Cell Carcinoma (RCC)
44 locations incl. Phoenix
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022
Exelixis Clinical
Clinical research site in Boston, Massachusetts · 36 GLOUCESTER ST STE 400, BOSTON, MA 02115-2509 · (978) 387-4415
Part of Exelixis Clinical
As of July 2026, 2 paid clinical trials are recruiting at Exelixis Clinical in Boston, Massachusetts. Active studies at this site cover conditions such as Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Urothelial Carcinoma (UC). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Exelixis Clinical (2)
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
for Solid Tumor
11 locations incl. San Francisco
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT06952010·Phase 1·Recruiting·Listed Apr 2025
More research sites in Boston
- Massachusetts General Hospital (694 trials)
- Brigham and Women's Hospital (346 trials)
- Dana-Farber Cancer Institute (341 trials)
- Beth Israel Deaconess Medical Center (265 trials)
- Boston Children's Hospital (259 trials)
- Dana Farber Cancer Institute (221 trials)
- Tufts Medical Center (107 trials)
- Boston Medical Center (94 trials)
- Massachusetts General Hospital Cancer Center (57 trials)
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA (28 trials)
Explore more
Paid clinical trials in Boston, MA · Massachusetts clinical trials